Top and Current
Source: (remove) : Nathan Rich
RSSJSONXMLCSV
Top and Current
Source: (remove) : Nathan Rich
RSSJSONXMLCSV
Mon, May 6, 2024
Mon, March 4, 2024
Mon, February 5, 2024
Wed, January 17, 2024
Tue, November 7, 2023
Thu, August 10, 2023
Wed, April 19, 2023
Fri, March 3, 2023
Thu, March 2, 2023
Wed, March 1, 2023
Wed, November 16, 2022
Fri, November 4, 2022
Mon, August 8, 2022
Tue, August 2, 2022
Thu, July 21, 2022
Thu, May 19, 2022
Thu, May 12, 2022
Thu, April 21, 2022
Mon, March 7, 2022
Tue, March 1, 2022
Tue, December 14, 2021
Tue, November 9, 2021
Mon, March 8, 2021
Thu, November 19, 2020
Mon, July 27, 2020
Mon, December 16, 2019
Wed, January 3, 2018
Fri, May 6, 2016
Wed, January 7, 2015
Wed, March 13, 2013
Wed, October 10, 2012

Nathan Rich Maintained (AMRX) at Strong Buy with Increased Target to $8 on, May 6th, 2024


Published on 2024-10-28 11:00:36 - WOPRAI, Nathan Rich
  Print publication without navigation


Nathan Rich of Goldman Sachs, Maintained "Amneal Pharmaceuticals, Inc." (AMRX) at Strong Buy with Increased Target from $6.25 to $8 on, May 6th, 2024.

Nathan has made no other calls on AMRX in the last 4 months.



There are 2 other peers that have a rating on AMRX. Out of the 2 peers that are also analyzing AMRX, 0 agree with Nathan's Rating of Hold.



These are the ratings of the 2 analyists that currently disagree with Nathan


  • David Amsellem of "Piper Sandler" Maintained at Buy with Increased Target to $8 on, Thursday, March 21st, 2024
  • Balaji Prasad of "Barclays" Maintained at Buy with Increased Target to $8 on, Monday, January 29th, 2024